Morningstar research shows growing role for CROs and CDMOs

5 December 2023

With demand for outsourcing continuing to increase, US financial services firm Morningstar has published a report into the industry landscape, outlining the increasingly central role that the sector plays in drug and biologic development.

Major pharma and biotech companies have for some time relied on contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) to assist with drug discovery, development and manufacturing.

This trend is set to continue, according to Morningstar’s research, which finds that substantial investments in biologics will “create a tailwind for the CRO and CDMO industry,” due to the complexity of these molecules.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK